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FarnesoidX receptor critically determines theﬁbrotic response in
mice but is expressed to a low extent in human hepatic stellate
cells and periductal myoﬁbroblasts. Fickert P, Fuchsbichler A,
Moustafa T, Wagner M, Zollner G, Halilbasic E, Stöger U, Arrese
M, Pizarro M, Solís N, Carrasco G, Caligiuri A, Sombetzki M,
Reisinger E, Tsybrovskyy O, Zatloukal K, Denk H, Jaeschke H,
Pinzani M, Trauner M. Am J Pathol. 2009 Dec;175(6):2392–
2405. Copyright (2009) American Society for Investigative
Pathology. Abstract published with permission from Elsevier.
http://www.ncbi.nlm.nih.gov/pubmed/19910507
Abstract: The nuclear bile acid receptor, farnesoid X receptor (FXR),
may play a pivotal role in liver ﬁbrosis. We tested the impact of
genetic FXR ablation in four different mouse models. Hepatic ﬁbrosis
was induced in wild-type and FXR knock-out mice (FXR(/)) by
CCl(4) intoxication, 3,5-diethoxycarbonyl-1,4-dihydrocollidine feed-
ing, common bile duct ligation, or Schistosoma mansoni (S.m.)-infec-
tion. In addition, we determined nuclear receptor expression levels
(FXR, pregnane X receptor (PXR), vitamin D receptor, constitutive
androstane receptor (CAR), small heterodimer partner (SHP)) in
mouse hepatic stellate cells (HSCs), portal myoﬁbroblasts (MFBs),
and human HSCs. Cell type-speciﬁc FXR protein expression was
determined by immunohistochemistry in ﬁve mouse models and pro-
totypic human ﬁbrotic liver diseases. Expression of nuclear receptors
was much lower in mouse and human HSCs/MFBs compared with
total liver expression with the exception of vitamin D receptor. FXR
protein was undetectable in mouse and human HSCs and MFBs.
FXR loss had no effect in CCl(4)-intoxicated and S.m.-infected mice,
but signiﬁcantly decreased liver ﬁbrosis of the biliary type (common
bile duct ligation, 3,5-diethoxycarbonyl-1,4-dihydrocollidine). These
data suggest that FXR loss signiﬁcantly reduces ﬁbrosis of the biliary
type, but has no impact on non-cholestatic liver ﬁbrosis. Since there
is no FXR expression in HSCs and MFBs in liver ﬁbrosis, our data indi-
cate that these cells may not represent direct therapeutic targets for
FXR ligands.Journal of Hepatology 20
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The farsenoid X receptor (FXR/NR1H4) is a member of the ligand-
activated nuclear receptor superfamily, which also includes the
pregnane X receptor (PXR/NR1I2), the constitutive androstane
receptor (CAR/NR1I3), and the vitamin D receptor (VDR/NR1I1)
[1]. FXR, which acts as a bile acid sensor, is mainly expressed in
the liver, intestine, kidney, and adrenal glands [2]. In the liver,
it has been identiﬁed and characterized as an important regulator
of key metabolic pathways involving bile acids, glucose, choles-
terol, and lipids, as well as of homeostatic liver functions such
as tissue regeneration and inﬂammatory response to tissue injury
[3,4]. Regarding the involvement of FXR receptor in the inﬂam-
matory response, it has been shown that FXR-deﬁcient (FXR/)
mice subjected to common bile duct ligation (BDL), to mimic
exposure to endogenous bile acids, demonstrate a less prominent
ductular reaction and reduced biliary infarcts as compared to
their wild-type littermates [5]. A 2004 study demonstrated
expression of FXR in quiescent and activated rat hepatic stellate
cells (HSC), suggesting that HSC may transduce bile acid-medi-
ated signals into scar production [6]. (Please note that here we
are using a strict deﬁnition of hepatic stellate cells, meaning per-
icyte-like cells of the hepatic sinusoid that undergo myoﬁbroblas-
tic differentiation in chronic liver injury.) During the
development of liver ﬁbrosis, activated or myoﬁbroblastic HSC
are, with portal myoﬁbroblasts (PMF), critically important extra-
cellular matrix-producing cells and are, therefore, considered to
be important targets in attempts to ﬁnd newmeans of preventing
or reducing liver ﬁbrosis. Taken together, these observations sug-
gest that FXR could be involved in the modulation of liver
ﬁbrogenesis.
The current study was designed to examine the role of FXR in
liver ﬁbrosis through a series of complementary experiments, by
a group with esteemed expertise in signaling mechanisms in cho-
lestasis. To test whether FXR expression could impact hepatic
ﬁbrogenesis, Fickert et al. subjected wild-type and FXR/ mice
to standard experimental ﬁbrosis models: 3,5-diethoxycarbon-
yl-1,4-dihydrocollidine (DDC) feeding, BDL, carbon tetrachloride
(CCl4) intoxication, and Schistosoma mansoni (S. mansoni) infec-
tion. The DDC intoxication and BDL models were used as models
of biliary cirrhosis, CCl4 intoxication as a model of non-biliary11 vol. 55 j 939–940
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cirrhosis, and S. mansoni infection as a model of non-biliary liver
ﬁbrosis. The authors show that, while having no signiﬁcant
impact on ﬁbrosis in CCl4 intoxication and S. mansoni infection
models, the genetic deletion of FXR is clearly associated with
decreased liver ﬁbrosis in cholestatic DDC intoxication and BDL
models. This ﬁnding is of critical importance, as it supports the
emerging notion that biliary cirrhosis may be a pathophysiologi-
cally distinct event from non-biliary cirrhosis. Speciﬁcally, biliary
cirrhosis may be mediated by epithelial–mesenchymal interac-
tions involving bile duct epithelia (BDE) and portal ﬁbroblasts
and/or hepatic stellate cells [7]. However, caution is always
required when interpreting data obtained using the constitutive
gene knock-out approach in mice, because such animals may
exhibit an adapted phenotype. This is an important consider-
ation, especially with the well-documented evidence of crosstalk
pathways between the targeted FXR receptor and other nuclear
receptors, for instance PXR and CAR receptors [8].
The latter set of studies in this paper was designed to deter-
mine the liver cell subpopulations expressing FXR and related
proteins. Mouse and human ﬁbrotic livers were used for histo-
morphometric (sirius red staining for collagen and hydroxypro-
line contents) and immunostaining studies, and studies were
made of isolated primary murine HSC and PMF. In congruence
with previous reports, the cells found to express FXR immunoge-
nicity in tissue sections from mouse and human were hepato-
cytes and BDE (with notably weaker staining in BDE). In
contrast with previous reports [6], however, no evidence of FXR
mRNA was detected in mouse PMF, and FXR mRNA was either
absent or present in very low levels in mouse HSC. Furthermore,
no evidence of the FXR effector small heterodimer partner (SHP)
or the bile acid importer sodium-taurocholate cotransporting
polypeptide (Ntcp) was noted in PMF, and Ntcp expression in
HSC was absent or minimal. The low/minimal expression of Ntcp
in HSC is echoed by our own unpublished studies, in which we
were unable to demonstrate inﬂux of bile acids into HSC. These
ﬁndings suggest that the beneﬁcial effects of FXR gene deletion
in experimental biliary cirrhosis are not mediated at the level
of liver myoﬁbroblasts. Of note, regarding the methodology
employed here, in situ hybridization experiments might have
effectively complemented the FXR gene expression studies, as
PCR- and antibody-based analyses may occasionally produce
inconsistent uneven results, especially when studying primary
isolated cells.
Is there a hypothesis that satisﬁes the observations in this
manuscript and related work in the ﬁeld? We believe that there
is. Speciﬁcally, it appears that BDE are themselves critical regula-
tors of biliary cirrhosis [9]. The pathologic hallmark of cholestatic
conditions leading to biliary cirrhosis is the development of the
ductular reaction, characterized by hyperproliferation of BDE
and an inﬂammatory inﬁltrate. The ductular reaction may indeed
indicate the starting point of the ﬁbrogenic process in biliary cir-
rhosis [7]. In relation to the current work, BDE are known to
express FXR [10,11] and, because the loss of FXR has been associ-
ated with reduced ductular proliferation in bile duct-ligated
FXR/mice ([5], and Supplementary Fig. 6 from the current man-
uscript), it is tempting to speculate that genetic FXR ablation
could, in fact, alter the phenotypic activation of BDE by blocking
their ability to transduce pro-ﬁbrogenic signals to liver myoﬁbro-
blasts. It is also interesting to note that, when DDC intoxication
and BDL models are compared, the mRNA levels of downstream940 Journal of Hepatology 201FXR target SHP are regulated in an opposite manner: signiﬁcantly
higher (Fig. 3E, DDC) and lower (Fig. 4E, BDL) than controls,
respectively, in wild-type mice, suggesting that the resistance
to liver ﬁbrosis conferred by genetic FXR silencing in these mod-
els is not dependent on the FXR–SHP axis, and this is supported
by the fact that the authors noted no protection from BDL-
induced ﬁbrosis in SHP (/) mice.
The major controversy to be found in this work is the func-
tional absence of FXR in mouse and human liver myoﬁbroblasts,
in stark contrast to the ﬁndings of Fiorucci et al. [6], who found
clear evidence of FXR mRNA and protein in rat HSC and the
related HSC-T6 cell line. A simple explanation would involve an
interspecies difference; however, this is not altogether reassur-
ing. Since both investigative groups are known for their experi-
mental expertise, it is difﬁcult to consider technical errors as
the primary explanation. Another possibility is the lack of
purity of preparations of liver cell subpopulations, even by expert
investigators, although this possibility would not account for the
ﬁnding of FXR in a passaged cell line. This is certainly a situation
warranting independent conﬁrmation of both laboratories’
ﬁndings by outside investigators, and this is of key importance,
since it would strongly inﬂuence new therapies to be designed
on the FXR axis for the prevention and/or treatment of liver
ﬁbrosis.Conﬂict of interest
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